Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 update for BT5528 (EphA2) in Solid tumor/s, Cancer. The expected timing is based on the latest available company guidance and may change.
07/30/26:- Ph1/2 mUC combo showed promising activity and differentiated safety at AACR 2026.
Verification
Confirm timing and program details against the company announcement or filing.